Brian Marckx
Brian Marckx
Send Message
Brian Marckx
Stop FollowingBrian Marckx
View as an RSS Feed
View Brian Marckx's Articles BY TICKER:
- CryoPort's Game-Changer In Frozen Biological Shipping
- Sanuwave: DermaPACE Could Be Very Competitive In $2B Diabetic Foot Ulcer Market
- Competitive Advantages, Huge Skin Cancer Market Bode Well For Aura
-
OptimizeRx's SampleMD Revolutionizing Prescription Drug Sampling
-
BioLife Has More Room To Run
-
VolitionRx Could Be A Game Changer In Cancer Detection
- ICAD's Double-Digit Growth Looks Sustainable
- Is This The Inflection Point For OptimizeRx?
- Chembio Caps 2012 With Another Revenue Record
- iCAD Q4 Results - Revenue Remains Strong, Expense Control Impressive
- Put Response Biomedical On Your Radar
- Rockwell Medical: Q3 Expenses Jump, Calcitriol Launch Pushed Back Again
- ICAD's Axxent Revenue Jumps To Record Quarter, Ripe For Revenue And Earnings Growth
-
Rockwell Medical Overvalued Based On Significant Risk
-
Chembio's Q2: Continued Strong Revenue Growth, OTC Program Moving Forward
- Electromed: Revenue Soft Again
- Chembio's Rise: Regulatory Process For DPP HIV Test On Track
- OptimizeRx Earnings Recap: Management Expects Accelerating Revenue In 2012
- CryoPort's Business Update Call Offers Insight
- Earnings Recap: Chembio's Record Q4
- Transgenomic: Q4 Results Beat On Top And Bottom
- Trinity Biotech Q4 Results Miss But Revenue Growth Guidance In Line
- iCAD Q4 Results: IORT Reimbursement Issue Impacting Revenue Ramp
- CryoPort's Adoption Is Slow But Progressing
- Corgenix Earnings Miss Slightly, Outlook Largely Unchanged
- Electromed Q2 Misses Big On Sales Force Disruption
- Transgenomic's Equity Financing Seems Like Overkill
- What's Ahead For Trinity Biotech
- OptimizeRx's Q3 Results: More Revenue Traction In Q4?
- CryoPort Q2 Results, Momentum Gain Show It's Undervalued
- Corgenix Medical Should Quickly Recoup Revenue Miss
- Sanuwave Q3 Results In Line; Shares Still Cheap
